RMC-6236-301

• Research type

  Research Study

• Full title

  RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

• IRAS ID

  1011716

• Contact name

  Minoti Hiremath

• Contact email

  mhiremath@revmed.com

• Sponsor organisation

  Revolution Medicines Inc

• ISRCTN Number

  ISRCTN17936325

• Clinicaltrials.gov Identifier

  NCT06881784

• Research summary

  This is a randomized, open-label study. There will be a pre-screening period up to 14 days during which study doctors will see if the
  patient’s tumor has RAS mutation. This is followed by a screening period up to 28 days (when patients meet with study doctors and undergo tests to see if they can join the study). This is followed by a treatment period and a follow-up period. During the treatment period, half of the patients will receive RMC-6236 and the other half will receive docetaxel. This is followed by a treatment period and a follow-up period.

• REC name

  North of Scotland Research Ethics Committee 1

• REC reference

  25/NS/0056

• Date of REC Opinion

  24 Jun 2025

• REC opinion

  Further Information Favourable Opinion